Premium
Clinicopathological characteristics and prognostic factors for canine multicentric non‐indolent T‐cell lymphoma: 107 cases
Author(s) -
Purzycka Katarzyna,
Peters Laureen M.,
Desmas Isabelle,
Davies Owen,
Chang YuMei,
LaraGarcia Ana
Publication year - 2020
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12589
Subject(s) - lomustine , medicine , canine lymphoma , lymphoma , gastroenterology , immunophenotyping , procarbazine , oncology , bone marrow , pathology , flow cytometry , vincristine , immunology , chemotherapy , cyclophosphamide
Abstract Canine lymphoma, as the most common haematopoietic malignancy, encompasses a group of heterogeneous diseases and even within the T‐cell immunophenotype, differences in clinical presentation and responses to treatment exist. The aim of this retrospective study was to determine outcomes and prognostic factors of 107 dogs with multicentric non‐indolent T‐cell lymphoma (TCL) receiving lomustine‐based (70%) and non‐lomustine‐based (30%) treatment. The majority were Labradors, Boxers, mixed‐breed dogs and Dogue de Bordeaux. Eighty‐six percent were substage b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement and 12% had other extra‐nodal sites of disease. The overall response rate to induction therapy was 80%; dogs receiving procarbazine in the induction protocol ( P = .042), dogs with neutrophil concentration below 8.7 × 10e 9 /L ( P = .006) and mitotic rate below 10 per 5 high power field ( P = .013), had greater response rates. Median progression‐free survival (PFS) for the first remission was 105 days; lack of expression of CD3 on flow cytometry ( P < .0001) and pretreatment with steroid ( P = .012) were significantly associated with shorter PFS. Median overall survival time (OST) was 136 days; co‐expression of CD79a ( P = .002), lack of CD3 expression on flow cytometry, presence of anaemia ( P = .007), and monocytopenia ( P = .002) were predictive of shorter OST. Multicentric non‐indolent TCL in dogs is an aggressive cancer with new possible prognostic factors.